MARKET

PHIO

PHIO

Phio Pharmaceuticals Corp
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.400
+0.020
+0.84%
Opening 10:37 09/22 EDT
OPEN
2.390
PREV CLOSE
2.380
HIGH
2.410
LOW
2.350
VOLUME
43.20K
TURNOVER
--
52 WEEK HIGH
18.15
52 WEEK LOW
1.600
MARKET CAP
13.87M
P/E (TTM)
-0.2005
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Sorrento Therapeutics, Phio Pharmaceuticals leads healthcare gainers, Strongbridge Biopharma, Nano-X Imaging among major losers
Gainers: Sorrento Therapeutics (SRNE) +24%, Entera Bio (ENTX) +23%,  Vaccinex (VCNX) +17%, Vaxart (VXRT) +15%, Phio Pharmaceuticals (PHIO) +14%Losers: Strongbridge Biopharma (SBBP) -19%, Nano-X Imaging (NNOX) -16%, Checkpoint Therapeutics (CKPT) -14%, NuCana (NCNA) -11%, Inovio Pharmaceuticals (INO) -11%.
Seekingalpha · 4d ago
Phio Pharmaceuticals to Present at the H.C. Wainwright 22nd Annual Global Investment Conference
Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today announced that its chief executive officer, Dr. Gerrit Dispersyn, will present at the
PR Newswire · 09/09 11:05
Phio Pharmaceuticals EPS beats by $0.31
Phio Pharmaceuticals (PHIO): Q2 GAAP EPS of -$0.34 beats by $0.31.Cash balance of $18.9M.Press Release
Seekingalpha · 08/12 21:14
Phio Pharmaceuticals EPS beats by $0.31
Phio Pharmaceuticals (PHIO): Q2 GAAP EPS of -$0.34 beats by $0.31.Cash balance of $18.9M.Press Release
Seekingalpha · 08/12 21:14
Phio Pharmaceuticals Q2 EPS $(0.34) Down From $(0.08) YoY
Phio Pharmaceuticals (NASDAQ:PHIO) reported quarterly losses of $(0.34) per share. This is a 325 percent decrease over losses of $(0.08) per share from the same period last year.
Benzinga · 08/12 21:01
Phio Pharmaceuticals Files Patent Application For 'Chemically Modified Oligonucleotides'
https://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PG01&s1=20200215113&OS=20200215113&RS=202002
Benzinga · 07/09 20:17
U.S. debut on horizon for iTeos Therapeutics
Seeking Alpha - Article · 06/25 16:10
Phio Presents Additional Data Supporting Potential of TIGIT Targeting INTASYL Compound in the Tumor Microenvironment at AACR 2020
PR Newswire · 06/22 14:00
More
Forecast
EPSBVPSCFPS
Actual (K USD)
Estimate (K USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average PHIO stock price target is 2.000 with a high estimate of 2.000 and a low estimate of 2.000.
EPS
Institutional Holdings
Institutions: 21
Institutional Holdings: 1.01M
% Owned: 17.52%
Shares Outstanding: 5.78M
TypeInstitutionsShares
Increased
2
43.61K
New
7
-596.01K
Decreased
2
22.34K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.85%
Pharmaceuticals & Medical Research
-0.54%
Key Executives
Chairman/Director
Robert Bitterman
President/Chief Executive Officer/Chief Operating Officer
Gerrit Dispersyn
Other
John Barrett
Director
Geert Cauwenbergh
Independent Director
H. Paul Dorman
Independent Director
Jonathan Freeman
Independent Director
Curtis Lockshin
  • Dividends
  • Splits
  • Insider Activity
No Data

Analyst Price Target

The average PHIO stock price target is 2.000 with a high estimate of 2.000 and a low estimate of 2.000.

Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About PHIO
Phio Pharmaceuticals Corp, formerly RXi Pharmaceuticals Corporation, is a biotechnology company. The Company is focused on developing immuno-oncology therapeutics based on its self-delivering ribonucleic acid interface (RNAi) (sd-rxRNA) therapeutic platform. The Company’s focuses on developing sd-rxRNA therapeutic compounds to be used in the context of adoptive cell transfer by targeting checkpoints or other gene targets, or to be used in immunotherapy following intratumoral injection. The Company’s pipeline include RXI-762 and RXI-804. Its sd-rxRNA compounds are designed to down-regulate the expression of a specific gene that may be over-expressed in a disease condition. The Company is developing RXI-762 for the treatment of Melanoma, Ovarian cancer and other indications. RXI-804 is an sd-rxRNA compound that is designed to suppress the expression of immune checkpoint protein, TIGIT.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Phio Pharmaceuticals Corp stock information, including NASDAQ:PHIO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PHIO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PHIO stock methods without spending real money on the virtual paper trading platform.